Bot Image™, Inc. Their flagship product, ProstatID™, is a computer-aided diagnosis (CADx) software device designed to assist radiologists in assessing and characterizing prostate abnormalities using MRI images. ProstatID™ automatically registers images, segments the central gland and entire prostate organ, and analyzes them to identify suspicious abnormalities.

It employs a pixel-wise random forest learning-based method, leveraging various features referenced to ground truth data on which it was trained. ProstatID™ received FDA clearance for marketing on July 8, 2022. Bot Image’s software is powered by advanced AI algorithms that interpret multi-parametric and bi-parametric MRI data using random forest with instance weight and MR segmentation by deep learning with holistically-nested networks.

The company has trained ProstatID™ using thousands of proprietary MR image sets, radiologist interpretations, segmented prostate gland image sets, pathology laboratory results, and correlation data to aid in the early detection of prostate cancer. With a vision to revolutionize medicine, Bot Image, Inc. Their highly advanced, non-invasive technology promises to deliver a sensitivity rate of over 90%, along with high specificity and the near elimination of false positives and false negatives.

The company also plans to expand the application of their AI algorithms to address the early diagnosis of other cancers and chronic obstructive pulmonary disease (COPD). To learn more about Bot Image and their cutting-edge technology, visit their website or reach out to their dedicated sales team